drugset
Drugs / CC-5103
last change Apr 2008 re-read 3 minutes ago

CC-5103

Developed for
Waldenstrom macroglobulinemia
Investigated by
Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Celgene Corporation · Dana-Farber Cancer Institute · Genentech, Inc.

Trials 1

today NCT00142168 · Ph 2
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00142168 Sep 2004 → May 2006 Waldenstrom macroglobulinemia Dana-Farber Cancer Institute Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CC-5103 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00142168 ↗
Route Oral “will be administered orally once daily” NCT00142168 ↗